AXOGUARD NERVECAP
Device
AXOGEN
Total Payments
$255,897
Transactions
119
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $69,146 | 28 | 0 |
| 2022 | $41,569 | 36 | 0 |
| 2021 | $145,182 | 55 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $255,897 | 119 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of Axoguard Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain (REPOSE) | AXOGEN | $248,561 | 0 |
| Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends (REPOSE-XL) | AXOGEN | $7,336 | 0 |
Top Doctors Receiving Payments for AXOGUARD NERVECAP
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Puyallup, WA | $255,897 | 119 |
About AXOGUARD NERVECAP
AXOGUARD NERVECAP is a device associated with $255,897 in payments to 0 healthcare providers, recorded across 119 transactions in the CMS Open Payments database. The primary manufacturer is AXOGEN.
Payment data is available from 2021 to 2023. In 2023, $69,146 was paid across 28 transactions to 0 doctors.
The most common payment nature for AXOGUARD NERVECAP is "Unspecified" ($255,897, 100.0% of total).
AXOGUARD NERVECAP is associated with 2 research studies, including "Study of Axoguard Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain (REPOSE)" ($248,561).